Document is current
Any future updates will be listed below
-
Authors
Beauchamp, Erwan
Yap, Megan C.
Iyer, Aishwarya
Perinpanayagam, Maneka A.
Gamma, Jay M.
Vincent, Krista M.
Lakshmanan, Manikandan
Raju, Anandhkumar
Tergaonkar, Vinay
Tan, Soo Yong
Lim, Soon Thye https://orcid.org/0000-0002-0366-5505
Dong, Wei-Feng
Postovit, Lynne M. https://orcid.org/0000-0002-8088-4197
Read, Kevin D. https://orcid.org/0000-0002-8536-0130
Gray, David W. https://orcid.org/0000-0001-9512-3828
Wyatt, Paul G.
Mackey, John R.
Berthiaume, Luc G. https://orcid.org/0000-0003-0926-059X
-
Funding
Funding for this research was provided by:
Alberta Innovates Translational Health Chair
Alberta Cancer Foundation (26380, 26362, 26927)
- License Information
-
More Information
Article History
Received: 18 November 2019
Accepted: 18 September 2020
First Online: 22 October 2020
Competing interests
: As co-founders of Pacylex Pharmaceuticals Inc. (www.pacylex.com), which owns the rights to patent applications PCT/2012/000696 and PCT/2013/050821, L.G.B., J.R.M., E.B., M.A.P., J.M.G., and M.Y. declare potential competing interests. To minimize these, cell line screens and animal xenograft studies were performed at arms length of the Pacylex co-founders. All the other authors declare no competing interests.
